Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
REGN.US
id: 1460
Regeneron Pharmaceuticals (REGN) Pricing Misrepresentation Case
S.D. New York
Court1:25-cv-00145
Case number11/02/2023
Class period Start10/30/2024
Class period End03/10/2025
Lead Plaintiff motion deadline- $REGN investors filed a lawsuit against Regeneron Pharmaceuticals for misrepresenting its pricing practices and financial performance related to its flagship drug.
- On April 10, 2024, the DOJ accused Regeneron of failing to include certain discounts in Eylea’s pricing calculations, inflating Medicare reimbursements. Following this news, $REGN dropped by 3.36%.
Case Details:
Between November 2, 2023, and October 30, 2024, Regeneron assured investors that its finances were strong, supported by stable pricing and growing demand for its popular eye treatment, Eylea, and its higher-dose version, Eylea HD.
On April 10, 2024, the DOJ accused Regeneron of inflating Medicare reimbursements by failing to include certain discounts, such as credit card fee reimbursements, in Eylea’s pricing calculations.
On October 31, 2024, Regeneron reported disappointing sales for Eylea HD, blaming reduced pricing power and growing competition. These revelations raised doubts about Regeneron’s transparency and compliance.
Following this, $REGN dropped by 3.36%.
Based on these events, $REGN investors filed a lawsuit against Regeneron Pharmaceuticals, accusing the company of the following:
- It misled investors about its pricing practices and compliance with Medicare regulations.
- It overstated financial stability tied to its flagship product, Eylea.
Investors believe Regeneron concealed critical pricing risks and overstated Eylea’s performance.
Case Status
Initial Complaint
Alleged Offence
Misleading Statements,
Financial Misrepresentation,
Fraud,
Failure to Disclose
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
10/31/2024
Filing date
01/07/2025
Lead Plaintiff Deadline
03/10/2025